10 Oct - 24 Oct 2022Rights issue
Founded in 2012 as a spin-off from Chalmers University of Technology in Sweden, Fluicell is a public biotech company specializing in high resolution bioprinting and single-cell biology. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.
Fluicell’s ambition is to empower researchers to push the bounds of science for the benefit of human health. We strive to provide state-of-the-art microfluidic platforms and research solutions across bioprinting and single-cell biology. Under the Lab-on-a-tip® umbrella, we have gathered all our instruments, accessories and consumables that will help you create an efficient laboratory workflow and to accelerate progress towards your next discovery.
The offer in summary
Record date: 5 October 2022
Subscription period: 10 October - 24 October 2022
Subscription rights: Anyone who is a shareholder in the Company on the record date of October 5, 2022 has preferential rights to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit right. Six (6) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of five (5) newly issued shares and two (2) free-of-charge warrants of series TO 4.
Subscription price: SEK 12.50 per unit
The offer: Maximum of 2 443 493 units which corresponds to ca MSEK 30.5.
Trading with unit rights: 10 October - 19 October 2022
Marketplace: First North Growth Market
Financial advisor: Sedermera Corporate Finance